Skip to main content
. 2022 Jul 2;40(7):699–714. doi: 10.1007/s40273-022-01168-0

Fig. 3.

Fig. 3

Probabilistic sensitivity analysis of the cost effectiveness of molnupiravir versus best supportive care. MOV molnupiravir treatment, Supp supportive (care), QALYs quality-adjusted life-years